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Lipids Abnormality and Type 2 




Dyslipidemia and diabetes both are important risk factors for cardiovascular 
disease. Emerging evidence suggests that these two are closely related to each 
other, the so-called “dyslipidemia-insulin resistance-hyperinsulinemia” cycle. 
Recently, several new lipid subfractions, such as apolipoprotein (Apo)B, and 
ApoJ, have been reported to associate with insulin resistance and incident dia-
betes, which further claim the role of lipid in the pathophysiology of diabetes. 
Besides, dyslipidemia is also one of the most prevalent diabetic complications. 
Clinical guidelines have widely recommended lipid management among diabetic 
patients through lifestyle intervention and lipid-lowering medications, especially 
statins, to prevent cardiovascular outcomes.
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1. Introduction
Type 2 diabetes mellitus (T2DM) is among the most prevalent chronic disease [1], 
affecting approximately 463 million people in 2019, and more than 690 million are 
expected to be diagnosed by 2045 [2]. People diagnosed with T2DM have a 2–4-fold 
higher risk of developing cardiovascular disease (CVD) [3]. Despite significant 
advantages in the prevention strategies that lessen related risk factors, CVD remains 
the leading cause of morbidity and mortality in patients with T2DM [4].
T2DM and CVD both have multi-factorial etiology, and disorders of lipid 
metabolism is one of the coexistence features sharing by them. For the develop-
ment of CVD, the cumulation of ApoB-containing lipoproteins in the arterial wall 
would lead to lipid deposition and an atheroma initiation, resulting in the progres-
sion of atherosclerotic plaques, and eventually atherosclerotic vascular disease 
[5]. Therefore, lipid-lowering drugs, such as statins, have been recommended as 
front-line therapy for primary prevention of atherosclerotic CVD [6], and the state-
of-the-art therapy in dyslipidemia in diabetic patients [3, 7, 8]. For the potential 
mechanism between lipid metabolism and diabetes, one meta-analysis reported 
that lipid parameters, such as triglyceride (TG), and low-density lipoprotein (LDL), 
can reflect the risk of T2DM [9]. Other lipid subfractions, such as high-density 
lipoprotein cholesterol (HDL) and lipid-free ApoA-I, could also benefit glycemic 
control by increasing glucose uptake in skeletal muscle, improving beta-cell func-
tion, and decreasing insulin resistance through inhibiting the proinflammatory 
signal transduction pathways [10].
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Considering the rather complex components of lipid and different directions for 
the associations between different lipid components and diabetes [11], more efforts 
are needed to elucidate the relationships between lipid profile and diabetes.
2. Lipid abnormality and incident type 2 diabetes mellitus
There are six major lipoproteins exist in blood: chylomicrons, very-low-density 
lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipo-
protein (LDL); lipoprotein(a) (Lp(a)), and high-density lipoprotein (HDL) [12]. 
Dyslipidemia represents a cluster of lipid and lipoprotein abnormalities, including 
elevation of both fasting and postprandial TG, apolipoprotein (Apo)A, or ApoB. 
The prevalence of dyslipidemia is getting severer worldwide. According to the 2015 
Global Burden of Disease Study, the prevalence of elevated total cholesterol (TC) 
(≥200 mg/dL) was highest in the WHO European Region (54% for both sexes), 
followed by the WHO Region of the Americas (48% for both sexes). The WHO 
African Region and the WHO South-East Asia Region showed the lowest percent-
ages (23% and 30%, respectively) [13]. In China, the prevalence of dyslipidemia 
was 42.8% overall [14], with 4.3%, 2.4%, 14.7%, and 17.4% for the age-standardized 
prevalence of high TC, LDL, TG, and HDL, respectively [15].
Evidence suggests that the development of T2DM was closely associated 
with lipid abnormality [16–26]. A study based on the 2010–2012 China National 
Nutrition and Health Survey (CNNHS) reported that the prevalence of dys-
lipidemia was 39.9%, 46.8%, and 59.3% in participants with normal glucose, 
prediabetes, and T2DM [16]. Zhu et al. ‘s meta-analysis reported that there were 
positive associations between different lipid parameters and T2DM. Moreover, the 
standardized mean difference for the Atherogenic index of plasma (AIP, lg(TG/
HDL)) is 1.78 (95% confidence interval (CI): 1.04–2.52), which is higher than 
for other parameters (TG: 0.93, 95% CI: 0.78–1.09; TC: 0.46, 95% CI: 0.21–0.71; 
HDL-C: −0.89, 95%CI: −1.18 to −0.60; and LDL-C: 0.44, 95% CI: 0.11–0.77), 
suggesting AIP may be more closely associated with the risk of T2DM [9]. Results 
from the prospective cohort study (Multi-Ethnic Study of Atherosclerosis) found 
that elevated total ApoC-III concentrations were associated with a higher rate of 
diabetes, while ApoC-III-defined HDL subspecies displayed opposing associations: 
HDL lacking ApoC-III was inversely associated with incident diabetes, while no 
association was found for HDL containing ApoC-III. Further adjustment for plasma 
TG as a potential intermediate attenuated these associations [17]. Besides, not only 
baseline cross-sectional estimated or abnormal lipid level is related, Zheng et al. 
found that time-dependent TG/HDL ratios were also positively associated with 
future incident T2DM, which supports the change patterns for these parameters 
during the follow-up could intricate the development of diabetes [18]. Beshars et al. 
evaluated the relationship between diabetes and the increment in triglyceride levels 
within the normal range. Their results suggest that sustained increments in rising 
triglyceride levels, even within the accepted normal range, might pose a cumulative 
risk for the development of diabetes and impaired fasting glucose [19].
Despite the aforementioned epidemiologic evidence, the precise mechanisms 
of the associations are complex and remain unclear. Since the hallmark of T2DM 
is the inability of pancreatic beta-cells to produce adequate amounts of insulin, 
accompanied by reduced tissue responsiveness to insulin, also known as insulin 
resistance. Lipotoxicity caused by dyslipidemia plays an important role in the 
development and progression of insulin resistance [10]. It can disturb the utilization 
of insulin in peripheral target tissues (such as the liver), thus affecting the amount 
of lipids synthesis in the liver. So, elevated blood lipid can lead to insulin resistance, 
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which in turn aggravates the generation of lipid metabolism disorder [27–29]. More 
recently, Seo et al. found that ApoJ is a novel hepatokine targeting muscle glucose 
metabolism and insulin sensitivity through low-density lipoprotein receptor-related 
protein-2 (LRP2)-dependent mechanism, coupled with the insulin receptor signal-
ing cascade. In muscle, LRP2 is necessary for insulin receptor internalization, an 
initial trigger for insulin signaling, that is crucial in regulating downstream signal-
ing and glucose uptake. Of physiologic significance, deletion of hepatic ApoJ or 
muscle LRP2 causes insulin resistance and glucose intolerance [30].
3. Lipid-lowering medication and incident type 2 diabetes mellitus
Lipid-lowering medication plays an essential role in the current healthcare 
system, not only for the optimization of the lipid profile but also to reduce car-
diovascular risk [6, 12]. Recently, there is increased awareness of the possibility 
that lipid-lowering medications may affect glucose control and insulin resistance 
[31–33]. This phenomenon is reported in all classes of lipid-modifying agents, with 
differential effects of distinct drugs.
Some insights into this question emerged from some recent studies. Barak et 
al. systematically reviewed the related evidence and reported that both statins and 
niacin are associated with increased risk of impaired glucose control and develop-
ment of new-onset diabetes, as opposed to bile-acid sequestrants which display 
concomitant moderate lipid and glucose-lowering effects, and fibrates (particularly 
the pan-PPAR agonist bezafibrate) which may produce beneficial effects on glucose 
metabolism and insulin sensitivity [34]. Another recently published meta-analysis, 
which included 163,688 nondiabetic patients from thirty-three randomized con-
trolled trials, reported no significant association between 1-mmol/L reduction in 
LDL cholesterol and incident diabetes for statins or PCSK9 inhibitors. More inten-
sive lipid-lowering therapy (defined as the more potent pharmacological strategy, 
such as PCSK9 inhibitors, higher intensity statins, or statins) was associated with a 
higher risk of incident diabetes compared with less intensive therapy (active control 
group or placebo/usual care of the trial). Meta-regression analysis suggested that 
these results were mainly driven by a higher risk of incident diabetes with statins, 
whereas PCSK9 inhibitors were not associated with incident diabetes (P = 0.02 for 
interaction). Thus, among intensive lipid-lowering therapies, there was no indepen-
dent association between reduction in LDL cholesterol and incident diabetes [32].
The precise mechanisms for statin-induced diabetes remain unclear. However, 
several mechanisms have been proposed, including impaired insulin sensitivity, 
impaired insulin secretion, and compromised beta-cell function via enhanced 
intracellular cholesterol uptake due to inhibition of intracellular cholesterol syn-
thesis by statins [34]. Recently, genetic studies have added more evidence to this. 
LDL-lowering alleles in HMGCR, which encodes the statins’ molecular target, were 
associated with a higher risk of T2DM and higher body mass index [35]. A further 
larger-scale individual meta-analysis concluded that other LDL-lowering alleles, 
such as NPC1L1, PCSK9, ABCG5/G8, were also associated with a higher risk T2DM 
[31]. Nevertheless, it has to be stressed here that the cardiovascular benefits of 
statins far outweigh diabetes risk [3].
4. Type 2 diabetic dyslipidemia
Diabetic dyslipidemia is a cluster of plasma lipid and lipoprotein abnor-
malities that are metabolically interrelated among diabetic patients. It is mainly 
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characterized by increased TG levels, low HDL levels, and postprandial lipemia 
and contributes to the development of vascular complications [36]. Results from 
the 2010–2012 China National Nutrition and Health Survey (CNNHS) shown 
that the prevalence of dyslipidemia was 39.9%, 46.8%, and 59.3% in participants 
with normal glucose, prediabetes, and T2DM [16]. Another study using data from 
the 2010–2014 Diabetes Mellitus/Hypertension (DM/HT) study, which included 
140,557 Thai adults with diabetes, reported that the dyslipidemia prevalence of 
88.9% [37]. Despite the heterogeneity between different studies, the prevalence of 
diabetic dyslipidemia has grown gradually worldwide [4].
The pathophysiology of diabetic dyslipidemia is intricate and has not been fully 
understood [38]. Briefly speaking, changes in plasma lipoproteins among diabetic 
patients are affected by insufficient insulin function and hyperglycemia [39]. 
During the postprandial state, dietary fatty acids (FA) and cholesterol absorbed by 
the intestinal cells are incorporated as TG and cholesteryl esters into chylomicrons. 
In the capillary beds of adipocytes (especially in the fed state) and muscle, chylomi-
crons are the substrate for lipoprotein lipase (LPL), promoting lipolysis of chylo-
microns TG and the release of FA. Insulin regulates LPL activity at several levels, 
including gene expression, protein synthesis, and secretion, and LPL is reduced in 
insulin-resistant individuals with T2DM with a consequent increase in plasma TG 
and decrease in HDL [40].
5. Type 2 diabetic dyslipidemia and cardiovascular disease
Both diabetes and dyslipidemia are important risk factors for CVD development, 
powered by the dyslipidemia-insulin resistance-hyperinsulinemia cycle [41]. This 
makes patients with diabetes dyslipidemia much more vulnerable to CVD out-
comes. Results from the Multiple Risk Factor Intervention Trial (MRFIT) reported 
that among men who had diabetes at baseline, the absolute risk of coronary mortal-
ity at each level of blood cholesterol (for 20 mg/dL increments in TC starting from 
180 mg/dL to >280 mg/dL), was 3–5 times higher in the presence of diabetes [42]. 
The United Kingdom Prospective Diabetes Study (UKPDS) has provided further 
evidence of a similarly direct and continuous association of coronary disease risk 
with LDL concentration. Among newly diagnosed T2DM, one mmol/L increase in 
LDL was associated with a 57% increased risk of myocardial infarction [43].
Many former studies have widely reported the causal association between 
dyslipidemia and CVD. Due to the rather complex components of lipid profile, 
diagnosis of diabetic dyslipidemia is not always revealed by the lipid measures used 
in clinical practice, as LDL levels may remain within the normal range. Therefore, 
it is suggested to use non-HDL levels to reflect the whole lipid spectrum [12]. 
The 2019 ESC/EAS Guidelines stated that ApoB analysis is recommended for risk 
assessment, particularly in people with high TG, diabetes, obesity, or metabolic 
syndrome. ApoB can be used as an alternative to LDL-C, if available, as the primary 
measurement for screening, diagnosis, and management [6].
Since a higher risk of atherosclerotic vascular disease in diabetic patients, lipid 
management has been recommended by diabetes-related clinical guidelines [3, 7, 
8, 44, 45]. Consistent data have demonstrated the efficacy of statins, the first-
choice lipid-lowering treatment, in preventing cardiovascular events and reducing 
cardiovascular mortality in patients with diabetes. A meta-analysis including 
18,686 diabetic patients demonstrated that a statin-induced reduction of LDL by 
1.0 mmol/L was associated with a 9% reduction in all-cause mortality and a 21% 
reduction in the incidence of major CV events [46]. The newly released ADA’s 





































Density (g/mL) Diameter (nm) TGs (%) Cholesteryl 
esters (%)




Chylomicrons <0.95 80–100 90–95 2–4 2–6 1 ApoB-48 ApoA-I, A-II, A-IV, A-V
VLDL 0.95–1.006 30–80 50–65 8–14 12–16 4–7 ApoB-100 ApoA-I, C-II, C-III, E, A-V
IDL 1.006–1.019 25–30 25–40 20–35 16–24 7–11 ApoB-100 ApoC-II, C-III, E
LDL 1.019–1.063 20–25 4–6 34–35 22–26 6–15 ApoB-100
HDL 1.063–1.210 8–13 7 10–20 55 5 ApoA-I ApoC-II, C-III, E, M
Lp(a) 1.006–1.125 25–30 4–8 35–46 17–24 6–9 Apo(a) ApoB-100
Apo: apolipoprotein; HDL: high-density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; Lp(a): lipoprotein(a); PLs: phospholipids; TGs: triglycerides;  
VLDL: very-low-density lipoprotein.
*Adapted from: “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.” By Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon 
L, et al. Eur Heart J. 2020;41 [1]:111–88.
Table 1. 
Physical and chemical characteristics of human plasma lipoproteins*.
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for both primary and secondary CVD prevention among diabetes. The detailed 
guideline are listed according to age groups: for 20–39 years-old diabetic patients 
with atherosclerotic cardiovascular disease risk factors, statin therapy is highly 
recommended in addition to lifestyle therapy; for patients with diabetes aged 
40–75 years without atherosclerotic cardiovascular disease, use moderate-inten-
sity statin therapy (lowers LDL by 30–49%) in addition to lifestyle therapy; while 
for patients aged 50–70 years with diabetes, high-intensity statin therapy (lowers 
LDL by ≥50%) is recommended [8]. The 2013 ACC/AHA guideline emphasized 
statin therapy recommended for all patients with diabetes 40 to 75 years of age-
independent of baseline cholesterol [47].
Despite the CVD protective effect among diabetic patients, statin therapy has 
been associated with new-onset T2DM [31, 32]. A former study reported that for 
every 40 mmol/L reduction of LDL by statins, conversion to T2DM is increased by 
10% [48, 49]. Nevertheless, the benefits in terms of cardiovascular event reduction 
Target Statin treatment
ADA
For patients with diabetes aged 40–75 years without atherosclerotic cardiovascular disease, use moderate-
intensity statin therapy in addition to lifestyle therapy.
For patients with diabetes aged 20–39 years with additional atherosclerotic cardiovascular disease risk 
factors, it may be reasonable to initiate statin therapy in addition to lifestyle therapy.
In patients with diabetes at higher risk, especially those with multiple atherosclerotic cardiovascular disease 
risk factors or aged 50–70 years, it is reasonable to use high-intensity statin therapy.
In adults with diabetes and a 10-year atherosclerotic cardiovascular disease risk of 20% or higher, it may be 
reasonable to add ezetimibe to maximally tolerated statin therapy to reduce LDL cholesterol levels by 50% or 
more.
ESC/EASD
In patients with T2D at moderate CV risk, an LDL-C target 
of <2.6 mmol/L (<100 mg/dL) is recommended.
Statins are recommended as the first-choice 
lipid-lowering treatment in patients with 
DM and high LDL-C levels: administration 
of statins is defined based on the CV risk 
profile of the patient and the recommended 
LDL-C (or non-HDL-C) target levels.
In patients with T2D at high CV risk, an LDL-C target of 
<1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 
50% is recommended.
In patients with T2D at very high CV risk, an LDL-C target 
of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at 
least 50% is recommended.
CDS
The primary goal is to reduce LDL-C to the target (very 
high risk of ASCVD: <1.8 mmol/L, high risk of ASCVD: 
<2.6 mmol/L).
Statins are the preferred lipid-lowering 
drugs. Lipid-lowering therapy should 
start with a moderate-intensity statin, and 
the dose should be adjusted according to 
individual response to medication and 
tolerability.
LDL-C reduction by ≥50% may be used as an alternative 
target in the event of high baseline LDL-C and failure to 
reduce LDL-C to the target after 3 months of standard 
lipid-lowering therapy.
JDS
The primary goal of antidyslipidemic therapy is to control 
the LDL-C level to <120 mg/dL in patients without a history 
of coronary artery disease.
Statins are the agents of choice for hyper-
LDL-C in patients with diabetes.
The control goal for fasting triglyceride (TG) is <150 mg/dL.
The control goal for HDL-C is ≥40 mg/dL.
Table 2. 
Guidelines for the management of diabetic dyslipidemia using statin.
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greatly exceed the risks of statin therapy, and this has been confirmed in patients at 
low cardiovascular risk [46] (Tables 1 and 2).
6. Conclusion
Complex lipoprotein metabolism abnormalities could present both in the 
development and progression of type 2 diabetes, which indicates that lipid manage-
ment can prevent cardiovascular complications among diabetic patients and involve 
in the prevention of diabetes. Epidemiological studies suggest that lipid compo-
nents could be a marker for diabetes prediction, though it is still uncertain which 
lipid markers are of the most clinical value. Lipid control using a lipid-lowering 
medication, such as statins, could reduce CVD risk among the general population 
also diabetic people. However, it is necessary to consider statin diabetogenicity in 
clinical practice when the statin is indicated.
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